Navigation Links
Antipodean Pharmaceuticals Announces Results of Phase 2 Study of Lead Compound MitoQ(R)
Date:4/24/2008

- Full Results Presented at European Association for the Study of the Liver

Annual Meeting -

SAN FRANCISCO, April 24 /PRNewswire/ -- Antipodean Pharmaceuticals, Inc. announced today, at the European Meeting for the Study of the Liver (EASL), the positive results of a Phase 2 trial of its lead compound MitoQ(R) (mitoquinone) in liver disease. The trial, conducted by Dr. Edward Gane, Associate Professor of Medicine, New Zealand Liver Transplant Unit at Auckland City Hospital, successfully met the primary clinical endpoint, the reduction of elevated liver enzymes.

In the 28-day trial, 30 patients with the Hepatitis C virus (HCV) were enrolled to study the effects of MitoQ on elevated liver enzymes. Researchers measured patients' baseline levels of aminotransferase (ALT), an enzyme released into the blood that indicates damage to the liver. The double-blind trial randomized patients to one of three treatment groups: MitoQ 40mg/day, MitoQ(R) 80mg/day or placebo. The primary endpoint was the reduction of levels of ALT. Patients who received MitoQ showed a significant decrease in ALT levels at the end of the study compared with baseline levels. The decrease from baseline was 26.4% (p<0.002) for patients in the 40mg dose group, and 28% (p<0.05) for patients in the 80mg dose group. These results suggest that MitoQ can reduce necroinflammation and may halt disease progression to fibrosis or cirrhosis.

The drug was well tolerated with no significant safety issues. Commonly reported adverse events (AEs) included nausea, headache and vomiting, which were usually mild and well tolerated. Only one patient withdrew from the study due to nausea. There were no significant laboratory or ECG abnormalities observed and no serious adverse events (SAEs) were reported.

"In patients with chronic liver disease, including the two patient populations with the largest unmet need -- patients with chronic hepatitis C, who have failed
'/>"/>

SOURCE Antipodean Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Jazz Pharmaceuticals to Present at Morgan Stanley Conference
2. Aida Pharmaceuticals, Inc. Announces Availability of Downloadable Corporate Synopsis on its Website
3. ISTA Pharmaceuticals Announces Conference Call and Webcast of First Quarter 2008 Financial Results
4. Law Offices of Howard G. Smith Announces 21 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Vertex Pharmaceuticals Inc.
5. Amylin Pharmaceuticals Reports First Quarter Financial Results
6. Ferring Pharmaceuticals EUFLEXXA(TM) to Serve as Sponsor for Sprint Force America Masters Track Club
7. Access Pharmaceuticals Announces New Data on Angiolix(R)
8. Lotus Pharmaceuticals, Inc. Announces Fourth Quarter and Fiscal Year 2007 Results
9. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results
10. Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research
11. Alexion Pharmaceuticals Invites You to Participate in its First Quarter 2008 Results Conference Call and Web Cast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2014)... (SALT LAKE CITY)A computational tool developed at the University ... with unknown gene mutations in three separate cases, U ... new study in The American Journal of Human ... Re-ranking tool), identifies undiagnosed illnesses and unknown gene mutations ... proteins that code for genes are made, in individual ...
(Date:4/22/2014)... available in German . ... the University of Vienna and the Medical University of Vienna, ... how double stranded RNA, such as viral genetic information, is ... immune response against viral infection, the protein ADAR1 moves from ... viral RNA to inhibit reproduction of the virus. But how ...
(Date:4/22/2014)... be influenced by low exposure to testosterone in the ... how men,s testosterone levels may be determined before they ... of the hormone than others is important because testosterone ... the hormone have been linked to obesity, diabetes and ... responsible for producing testosterone in adults known as ...
(Date:4/22/2014)... most of us have gotten stuck in a check-out ... Will Mather, assistant professor of physics and an instructor ... lines, or queues, has been crucial in trying to ... recycling of proteins. , The work, submitted during Mather,s ... from the National Science Foundation in the form of ...
(Date:4/22/2014)... of Calgary,s Hotchkiss Brain Institute (HBI) uncovers a mechanism ... means to restore connections after injury. Dr. Doug Zochodne ... directly regulates nerve cell growth in the damaged nervous ... Nature Communications , with lead authors Drs. Kim ... surprising discovery that a protein called Retinoblastoma (Rb) is ...
Breaking Medicine News(10 mins):Health News:Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses 2Health News:Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses 3Health News:How the body fights against viruses 2Health News:How the body fights against viruses 3Health News:Queuing theory helps physicist understand protein recycling 2Health News:Scientists discover a new way to enhance nerve growth following injury 2
... the only over the counter treatment for chronic and acute wounds. ... contamination of wounds and speeds up the healing process. ... ... development of Wound-Be-Gone, all skin injuries, especially large, chronic wounds, can ...
... WASHINGTON, Nov. 18 Over 2 million low-income Medicare,beneficiaries ... in,January. Changes to the 2009 Medicare Part D plans ... premiums they cannot afford or limit,access to their prescriptions, ... Law Center (NSCLC). Part D open enrollment runs from ...
... But research is preliminary, scientists stress , , TUESDAY, Nov. ... a genetic trait that could provide an early indication ... The research, reported Tuesday at the American Association for ... the preliminary stages. , Still, "the benefit would hopefully ...
... A study appearing in Journal of the American ... their healthcare benefits may affect their ability to access ... delay or avoid seeking care. , In the ... across the United States were surveyed. About one-third of ...
... Resource So Families of ,Bad, Children Can Survive - and ... BEACH, Fla., Nov. 18 The holidays should bring peace, ... the season can foster difficult, even disorderly conduct among troubled ... a family gathering and leave parents asking, "What did I ...
... SEATTLE, Nov. 18 Seattle University ... million Opus Prize to Marguerite "Maggy",Barankitse for her ... of,ethnic strife in Burundi, Africa. Two $100,000 winners ... Community and Center for the,Development of Central America, ...
Cached Medicine News:Health News:A Revolution in Wound Healing, Wound-Be-Gone Now the Only Over the Counter Treatment for Chronic and Acute Wounds 2Health News:A Revolution in Wound Healing, Wound-Be-Gone Now the Only Over the Counter Treatment for Chronic and Acute Wounds 3Health News:2009 Medicare Part D Premiums to Rise Dramatically: Over 2 Million Low Income Beneficiaries At Risk 2Health News:Genetic Trait Could Predict Lung Cancer 2Health News:New Site DrNorm.com Offers Hope and Healing to Parents of 'Difficult' Children During Holiday Season & Beyond 2Health News:New Site DrNorm.com Offers Hope and Healing to Parents of 'Difficult' Children During Holiday Season & Beyond 3Health News:Seattle University in Partnership With the Opus Prize Foundation Award $1 Million Opus Prize 2
(Date:1/15/2014)... 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ... stock of Solta Medical, Inc. (NASDAQ: SLTM ...
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... results for the fourth quarter of 2013 on Monday, February ... for release after the close of trading. ... conference call to discuss the operating highlights and financial results ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... (NYSE: DHR ) announced today that Henk ... and Amir Aghdaei and Henrik Roos have each been ... In his new role, Henk van Duijnhoven will ... Group and Sybron Dental Specialties.  Danaher,s Dental segment generated ...
... ALISO VIEJO, Calif., April 5, 2011 Avanir Pharmaceuticals, Inc. ... will present an overview of the company at the Future Leaders ... Location: Millennium Broadway Hotel & Conference Center, New York, ... Presentation time: 2:00pm ET A live ...
Cached Medicine Technology:Danaher Announces Executive Appointments 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: